Discussing The Past, Present And Future Of Cell And Gene Therapies
Outgoing CEO Of The Cell and Gene Therapy Catapult, Keith Thompson, On Turning Groundbreaking Research Into A New Industry
Executive Summary
Founding CEO of the UK’s Cell and Gene Therapy Catapult, Keith Thompson, will retire from the company this year. He looks back on the last eight years of progress for CGT Catapult and the advanced therapies sector – and provides words of wisdom for the challenges still to come.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.